Today: 22 June 2026
Browse Category

Pharmaceuticals 9 June 2026 - 22 June 2026

AbbVie announced it will acquire Apogee Therapeutics for $135.11 per share in cash, valuing the biotech at about $10.9 billion. The deal brings AbbVie an experimental drug, zumilokibart, aimed at treating atopic dermatitis and other immune diseases. Pfizer shares declined over the past week following news that CFO Dave Denton will step down in August, with Cecile Guegan set to become interim CFO. Despite the leadership change, Pfizer maintained its 2026 forecast, but investors remain focused on succession plans, execution, and competition from obesity drug makers. Novo Nordisk shares rose around 5% as healthcare stocks outperformed in Europe, while the company continues to attract defensive investors. Outlook Therapeutics shares surged 30% after the FDA accepted its resubmitted application for ONS-5010/LYTENAVA, with a key FDA decision expected by July 29, 2026. Alumis gained over 15% as investors anticipate Phase 2b lupus results in the third quarter and a psoriasis NDA filing in the fourth quarter. Roche shares rose after announcing a $2.3 billion deal with Nurix Therapeutics for a late-stage blood-cancer asset. Nuvalent shares jumped nearly 40% after GSK agreed to acquire the company for $124 per share in cash. Eli Lilly reached a record high after releasing positive late-stage results for its experimental retatrutide injection in sleep apnea and knee osteoarthritis. Veru shares held gains after Novo Nordisk agreed to supply Wegovy for a Phase 2b obesity trial, signaling validation but with ongoing trial and financing risks.
Pfizer trades up with Rigel’s Veppanu deal done

Pfizer trades up with Rigel’s Veppanu deal done

Pfizer shares edged up 0.15% to $26.04 after Rigel closed a Veppanu licensing deal with Arvinas and Pfizer, triggering a $35 million payment to Pfizer; the deal highlights ongoing investor focus on whether Pfizer’s oncology and obesity pipeline can offset COVID declines and looming patent losses, with analysts split on pipeline potential versus slow growth and patent pressure.
17 June 2026
·····
CervoMed Shares Rise in Early Trade After $3 Million Insider-Related Purchase

CervoMed Shares Rise in Early Trade After $3 Million Insider-Related Purchase

CervoMed soared over 30% premarket after an SEC filing revealed a trust linked to board chair Joshua S. Boger bought $3 million in units above Monday’s close, signaling insider confidence following last week’s $10.5 million private placement that extends cash runway but raises dilution risks; the next key catalyst is securing a strategic partner for neflamapimod’s Phase 3 dementia with Lewy bodies program.
16 June 2026
··
Alumis Shares Surge 16% as Traders Eye New Drug Move

Alumis Shares Surge 16% as Traders Eye New Drug Move

Alumis soared 15.55% to $24.15 on double average volume after strong analyst support and late-stage psoriasis data, but remains a high-risk, loss-making biotech with no approved products; key investor focus is on Phase 2b lupus data due Q3 and a planned psoriasis NDA filing in Q4, with future stock moves hinging on these clinical and regulatory milestones.
12 June 2026
··
Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
11 June 2026
··
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
9 June 2026
··
1 2 3 … 42

Stock Market Today

  • Accenture Stock Plummets on Growth and AI Concerns
    June 22, 2026, 2:17 PM EDT. Analysts are slashing forecasts and price targets for Accenture following its disappointing earnings report. The company's outlook raised alarms over growth prospects, bookings, and acquisitions. Worries about potential disruption from artificial intelligence (AI) also weighed heavily on the stock. Investors fear Accenture's durability in the fast-evolving tech consulting space may be overstated, prompting a sharp selloff. This marks a significant setback for the firm's valuations amid broader market scrutiny of tech sector resilience.

Latest articles

AbbVie grabs Apogee in $10.9 billion deal as buyouts speed up

AbbVie grabs Apogee in $10.9 billion deal as buyouts speed up

22 June 2026
AbbVie surged 6.9% after announcing its $10.9 billion cash buyout of Apogee Therapeutics at a 49% premium, adding a late-stage eczema drug that could reduce injection frequency versus Dupixent; the deal aims to offset Humira losses and fill future revenue gaps, but risks remain if Phase 3 trials disappoint or the merger faces delays.
Russell Reconstitution 2026: NASDAQ:CRWV, NYSE:BE Lead the Great Index Migration

Russell Reconstitution 2026: NASDAQ:CRWV, NYSE:BE Lead the Great Index Migration

22 June 2026
FTSE Russell’s annual index reconstitution will force trillions in passive fund trades at Friday’s close, with CoreWeave joining the Russell 1000 and Bloom Energy moving up, driving concentrated order flows that can trigger sharp price swings in affected stocks, but inclusion or deletion alone does not guarantee immediate gains or losses.
Go toTop